色氨酸 20 号终止突变及其与结核分枝杆菌 4.5 谱系和对德拉马尼和贝达喹啉耐药性的关联。
The Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
机构信息
Public Health Agency of Swedengrid.419734.c, Solna, Sweden.
出版信息
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0102622. doi: 10.1128/aac.01026-22. Epub 2022 Nov 21.
Abstract
High-confidence resistance mutations for new and repurposed anti-TB drugs, such as delamanid (DLM) and pretomanid (Pa), are rare and more data are needed in order to correctly interpret the results generated by genotypic drug susceptibility testing. In this study performed on clinical Mycobacterium tuberculosis complex isolates, we report that in the Swedish strain collection the mutation Trp20Stop is found exclusively among DLM and Pa resistant (Pa MIC >16 mg/L) isolates assigned to lineage 4.5.
摘要
高可信度的耐结核新药（如德拉马尼[DLM]和普托马尼[Pa]）耐药突变较为罕见，需要更多数据才能正确解读基因型药物敏感性试验的结果。本研究对临床结核分枝杆菌复合群分离株进行分析，报告称在瑞典菌株集中，Trp20Stop 突变仅存在于 DLM 和 Pa 耐药（Pa MIC＞16mg/L）株中，且这些耐药株均属于谱系 4.5。
相似文献
1
The Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0102622. doi: 10.1128/aac.01026-22. Epub 2022 Nov 21.
2
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w. Epub 2019 Apr 5.
3
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.
J Clin Lab Anal. 2024 Aug;38(15-16):e25091. doi: 10.1002/jcla.25091.
4
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
J Antimicrob Chemother. 2023 Nov 6;78(11):2637-2644. doi: 10.1093/jac/dkad252.
5
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.
6
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Sci Rep. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4.
7
High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant isolates.
Emerg Microbes Infect. 2022 Dec;11(1):1857-1866. doi: 10.1080/22221751.2022.2099304.
8
Delamanid or pretomanid? A Solomonic judgement!
J Antimicrob Chemother. 2022 Mar 31;77(4):880-902. doi: 10.1093/jac/dkab505.
9
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00513-20.
10
Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0053122. doi: 10.1128/aac.00531-22. Epub 2022 Nov 30.
引用本文的文献
1
High-Level Primary Pretomanid-Resistant with In-Frame Deletion of and Its Association with Lineage 4.5 in China.
ACS Omega. 2025 Jun 23;10(25):26551-26559. doi: 10.1021/acsomega.5c00610. eCollection 2025 Jul 1.
2
Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the complex based on the EUCAST reference protocol.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0094624. doi: 10.1128/aac.00946-24. Epub 2024 Dec 18.
本文引用的文献
1
Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.
Front Microbiol. 2022 Mar 24;13:775030. doi: 10.3389/fmicb.2022.775030. eCollection 2022.
2
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
J Antimicrob Chemother. 2022 May 29;77(6):1685-1693. doi: 10.1093/jac/dkac070.
3
Delamanid or pretomanid? A Solomonic judgement!
J Antimicrob Chemother. 2022 Mar 31;77(4):880-902. doi: 10.1093/jac/dkab505.
4
Genomic signatures of pre-resistance in Mycobacterium tuberculosis.
Nat Commun. 2021 Dec 15;12(1):7312. doi: 10.1038/s41467-021-27616-7.
5
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Sci Rep. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4.
6
Adduct Formation of Delamanid with NAD in Mycobacteria.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01755-19.
7
Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex.
Genome Med. 2020 Mar 6;12(1):27. doi: 10.1186/s13073-020-00726-5.
8
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
PLoS Pathog. 2020 Feb 7;16(2):e1008287. doi: 10.1371/journal.ppat.1008287. eCollection 2020 Feb.
9
Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system.
J Antimicrob Chemother. 2016 Jun;71(6):1532-9. doi: 10.1093/jac/dkw044. Epub 2016 Apr 13.
10
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
PLoS Med. 2006 Nov;3(11):e466. doi: 10.1371/journal.pmed.0030466.
Zotero 插件